Jaguar Health announces publication on crofelemer development

Jaguar Health announced that an article about the company’s focus on developing its novel plant-based prescription drug crofelemer for two rare disease indications, short bowel syndrome and microvillus inclusion disease, was published August 23, 2023 in The Science Times. The article is titled “Jaguar Health supports Investigator Initiated Trials for Crofelemer to Treat Two Rare Intestinal Diseases”. Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for MVID and SBS with intestinal failure in the US, EU and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024. In accordance with the guidelines of specific European Union countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID, potentially in 2024, for these debilitating conditions.